首页 > 最新文献

Digestive medicine research最新文献

英文 中文
Hypercoagulable state from COVID-19 in a patient with primary biliary cholangitis—a case report COVID-19致原发性胆道胆管炎患者高凝状态1例报告
Pub Date : 2021-12-01 DOI: 10.21037/dmr-21-60
S. Saab, Mikhail A. Alper, Sommer Sekhon, E. Akhtar, Naeem Akhtar, B. Tafti, S. Tower, Robert D. Lemon, S. Masood
: Coronavirus disease, also known as COVID-19, is an infectious disease caused by a newly discovered coronavirus. Infected individuals can manifest hepatocellular pattern of elevated liver associated tests, with cholestatic patterns being less common. Here we highlight a patient with primary biliary cholangitis (PBC) who developed worsening cholestasis and extensive liver-related thrombosis after contracting COVID-19. A case of a 48-year-old woman with underlying PBC presented with worsening cholestasis after contracting COVID-19. The results of the liver associated test at the time of her COVID-19 presentation were remarkable for increased alkaline phosphatase (AP) value 1,050 IU/L. The results of an abdominal computed tomography (CT) demonstrated a thrombosis extending from infrarenal inferior vena cava (IVC) to the suprahepatic IVC and further extending into bilateral renal veins as well as an accessory right hepatic vein. She underwent successful thrombectomy on September 2020. The results of a follow up abdominal CT in March 2021 revealed no residual IVC thrombus. However, her serum AP remained elevated at 361 IU/L at last follow-up. Our primary aim is to highlight the possible association of COVID-19 infection and the hypercoagulability leading to worsening cholestasis in a patient with underlying PBC underlying disease post-infection. This case should alert providers to consider liver-related thrombosis in the differential with patients with PBC presenting with liver associated tests.
:冠状病毒病,也称为新冠肺炎,是一种由新发现的冠状病毒引起的传染病。受感染的个体可以表现出肝相关测试升高的肝细胞模式,胆汁淤积模式不太常见。在这里,我们重点介绍一名原发性胆汁性胆管炎(PBC)患者,他在感染新冠肺炎后出现了恶化的胆汁淤积和广泛的肝脏相关血栓形成。一例48岁患有潜在PBC的女性在感染新冠肺炎后出现胆汁淤积恶化。她出现新冠肺炎时的肝脏相关测试结果显示,碱性磷酸酶(AP)值增加1050 IU/L。腹部计算机断层扫描(CT)的结果显示,血栓从肾下下腔静脉(IVC)延伸到肝上下腔静脉,并进一步延伸到双侧肾静脉和肝右副静脉。她于2020年9月成功接受了血栓切除术。2021年3月的腹部CT随访结果显示没有残留的IVC血栓。然而,在最后一次随访中,她的血清AP仍升高至361IU/L。我们的主要目的是强调新冠肺炎感染与高凝状态导致感染后潜在PBC基础疾病患者胆汁淤积恶化的可能关联。该病例应提醒提供者将肝脏相关血栓与PBC患者进行肝脏相关检查进行区分。
{"title":"Hypercoagulable state from COVID-19 in a patient with primary biliary cholangitis—a case report","authors":"S. Saab, Mikhail A. Alper, Sommer Sekhon, E. Akhtar, Naeem Akhtar, B. Tafti, S. Tower, Robert D. Lemon, S. Masood","doi":"10.21037/dmr-21-60","DOIUrl":"https://doi.org/10.21037/dmr-21-60","url":null,"abstract":": Coronavirus disease, also known as COVID-19, is an infectious disease caused by a newly discovered coronavirus. Infected individuals can manifest hepatocellular pattern of elevated liver associated tests, with cholestatic patterns being less common. Here we highlight a patient with primary biliary cholangitis (PBC) who developed worsening cholestasis and extensive liver-related thrombosis after contracting COVID-19. A case of a 48-year-old woman with underlying PBC presented with worsening cholestasis after contracting COVID-19. The results of the liver associated test at the time of her COVID-19 presentation were remarkable for increased alkaline phosphatase (AP) value 1,050 IU/L. The results of an abdominal computed tomography (CT) demonstrated a thrombosis extending from infrarenal inferior vena cava (IVC) to the suprahepatic IVC and further extending into bilateral renal veins as well as an accessory right hepatic vein. She underwent successful thrombectomy on September 2020. The results of a follow up abdominal CT in March 2021 revealed no residual IVC thrombus. However, her serum AP remained elevated at 361 IU/L at last follow-up. Our primary aim is to highlight the possible association of COVID-19 infection and the hypercoagulability leading to worsening cholestasis in a patient with underlying PBC underlying disease post-infection. This case should alert providers to consider liver-related thrombosis in the differential with patients with PBC presenting with liver associated tests.","PeriodicalId":72814,"journal":{"name":"Digestive medicine research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45470416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Digestive Medicine Research (DMR) is now a member of Committee on Publication Ethics (COPE) 消化医学研究(DMR)现在是出版伦理委员会(COPE)的成员
Pub Date : 2021-12-01 DOI: 10.21037/dmr-21-101
{"title":"Digestive Medicine Research (DMR) is now a member of Committee on Publication Ethics (COPE)","authors":"","doi":"10.21037/dmr-21-101","DOIUrl":"https://doi.org/10.21037/dmr-21-101","url":null,"abstract":"","PeriodicalId":72814,"journal":{"name":"Digestive medicine research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47377524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Innovation and evolution of gastric surgery 胃外科的创新与发展
Pub Date : 2021-09-01 DOI: 10.21037/dmr-21-62
A. Guerron
{"title":"Innovation and evolution of gastric surgery","authors":"A. Guerron","doi":"10.21037/dmr-21-62","DOIUrl":"https://doi.org/10.21037/dmr-21-62","url":null,"abstract":"","PeriodicalId":72814,"journal":{"name":"Digestive medicine research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42193882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real World Data of thrombopoietin receptor for thrombocytopenia with chronic liver disease 血小板生成素受体治疗慢性肝病伴血小板减少症的真实数据
Pub Date : 2021-09-01 DOI: 10.21037/dmr-21-68
T. Ishikawa
© Digestive Medicine Research. All rights reserved. Dig Med Res 2021;4:41 | https://dx.doi.org/10.21037/dmr-21-68 Thrombocytopenia is one of major complication in chronic liver disease patients, with approximately 76% of patients having platelet counts <150,000/μL and approximately 13% having platelet counts between 50,000–75,000/μL (1). Periprocedural bleeding risk management is an essential strategy in chronic liver disease. Chronic liver disease patients frequently require invasive diagnostic and therapeutic procedures, such as liver biopsies, variceal band ligation, or percutaneous procedures such as radiofrequency ablation and microwave ablation for hepatocellular carcinoma (HCC) (2). However, these procedures may be delayed or sometimes canceled due to the risk of bleeding in patients who also have thrombocytopenia. Therefore, thrombocytopenia is a major issue in patients with chronic liver disease. Historically, the treatment options for thrombocytopenia in chronic liver disease have been platelet transfusions, either immediately before or during the procedure (3,4). Platelet transfusion has been established is considered the standard of care for managing thrombocytopenia in patients with chronic liver disease (3,4), and is supported by society guidelines, with platelet goals ≥50,000/μL widely recommended for many procedures (3,4). However, platelet transfusion has many disadvantages, such as increased risk of viral and bacterial infections (5), the development of febrile nonhemolytic reactions such as anaphylactic shock, anaphylaxis, hypotension, dyspnea, transfusion associated circulatory overload (TACO), and transfusion-related acute lung injury (TRALI) (6) and non-serious adverse reactions such as urticaria and fever. There are also problems such as the risk of infectious diseases and platelet transfusion refractoriness due to repeated transfusion due to human leukocyte antigen alloimmunization (7). Recently with the advance in the knowledge of thrombopoiesis and the role of its key regulator, thrombopoietin (TPO) led to the production of novel drugs that act as TPO receptor (TPO-R) agonists that activate and enhance megakaryopoiesis which in turn increase platelet synthesis (8). Hence, TPO, also known as Megakaryocyte Growth and Development Factor (MGDF) or c-MpL ligand, is a hormone which is synthesized in the liver and dominantly regulates the process of megakaryocytopoiesis (9). TPO acts on c-MpL receptor on the surface of megakaryocytes and stimulates various steps of platelet production within the bone marrow (10). TPO generation in turn is regulated by the rate of platelet cycling (production and destruction), as well as the synthetic function of liver (11). Several studies have argued about the relative majority influence on this multifactorial etiology of thrombocytopenia in CLD (11). Romiplostim and eltrombopag were developed as successful first generation TPO receptor agonists. Romiplostim is indicated for thrombocytopenia d
©消化医学研究。保留所有权利。Dig Med Res 2021;4:41|https://dx.doi.org/10.21037/dmr-21-68血小板减少症是慢性肝病患者的主要并发症之一,约76%的患者血小板计数<150000/μL,约13%的患者血小板数在50000-75000/μL之间(1)。围手术期出血风险管理是慢性肝病的重要策略。慢性肝病患者经常需要侵入性诊断和治疗程序,如肝活检、静脉曲张带结扎或经皮手术,如肝细胞癌(HCC)的射频消融和微波消融(2)。然而,由于同时患有血小板减少症的患者有出血的风险,这些手术可能会推迟或有时取消。因此,血小板减少症是慢性肝病患者的主要问题。从历史上看,慢性肝病血小板减少症的治疗选择是在手术前或手术过程中立即输注血小板(3,4)。血小板输注已被确定为治疗慢性肝病患者血小板减少症的护理标准(3,4),并得到社会指南的支持,许多手术广泛建议血小板目标≥50000/μL(3,3)。然而,血小板输注有许多缺点,如增加病毒和细菌感染的风险(5),出现发热性非溶血性反应,如过敏性休克、过敏反应、低血压、呼吸困难、输注相关循环超负荷(TACO)和输注相关急性肺损伤(TRALI)(6),以及非严重不良反应,如荨麻疹和发烧。还存在诸如感染性疾病的风险和由于人类白细胞抗原同种免疫引起的重复输注导致的血小板输注不成功等问题(7)。最近,随着对血小板生成及其关键调节因子作用的认识的进步,血小板生成素(TPO)导致了作为TPO受体(TPO-R)激动剂的新药的生产,该激动剂激活并增强巨核细胞生成,进而增加血小板合成(8)。因此,TPO,也称为巨核细胞生长发育因子(MGDF)或c-MpL配体,是一种在肝脏中合成的激素,主要调节巨核细胞生成过程(9)。TPO作用于巨核细胞表面的c-MpL受体,并刺激骨髓内血小板产生的各个步骤(10)。TPO的产生反过来受到血小板循环(产生和破坏)速率以及肝脏合成功能的调节(11)。几项研究争论了相对多数对CLD血小板减少症多因素病因的影响(11)。Romiplostim和eltrombopag被开发为成功的第一代TPO受体激动剂。Romiplostim适用于血液系统疾病引起的血小板减少症。因此,一些研究和案例编辑
{"title":"Real World Data of thrombopoietin receptor for thrombocytopenia with chronic liver disease","authors":"T. Ishikawa","doi":"10.21037/dmr-21-68","DOIUrl":"https://doi.org/10.21037/dmr-21-68","url":null,"abstract":"© Digestive Medicine Research. All rights reserved. Dig Med Res 2021;4:41 | https://dx.doi.org/10.21037/dmr-21-68 Thrombocytopenia is one of major complication in chronic liver disease patients, with approximately 76% of patients having platelet counts <150,000/μL and approximately 13% having platelet counts between 50,000–75,000/μL (1). Periprocedural bleeding risk management is an essential strategy in chronic liver disease. Chronic liver disease patients frequently require invasive diagnostic and therapeutic procedures, such as liver biopsies, variceal band ligation, or percutaneous procedures such as radiofrequency ablation and microwave ablation for hepatocellular carcinoma (HCC) (2). However, these procedures may be delayed or sometimes canceled due to the risk of bleeding in patients who also have thrombocytopenia. Therefore, thrombocytopenia is a major issue in patients with chronic liver disease. Historically, the treatment options for thrombocytopenia in chronic liver disease have been platelet transfusions, either immediately before or during the procedure (3,4). Platelet transfusion has been established is considered the standard of care for managing thrombocytopenia in patients with chronic liver disease (3,4), and is supported by society guidelines, with platelet goals ≥50,000/μL widely recommended for many procedures (3,4). However, platelet transfusion has many disadvantages, such as increased risk of viral and bacterial infections (5), the development of febrile nonhemolytic reactions such as anaphylactic shock, anaphylaxis, hypotension, dyspnea, transfusion associated circulatory overload (TACO), and transfusion-related acute lung injury (TRALI) (6) and non-serious adverse reactions such as urticaria and fever. There are also problems such as the risk of infectious diseases and platelet transfusion refractoriness due to repeated transfusion due to human leukocyte antigen alloimmunization (7). Recently with the advance in the knowledge of thrombopoiesis and the role of its key regulator, thrombopoietin (TPO) led to the production of novel drugs that act as TPO receptor (TPO-R) agonists that activate and enhance megakaryopoiesis which in turn increase platelet synthesis (8). Hence, TPO, also known as Megakaryocyte Growth and Development Factor (MGDF) or c-MpL ligand, is a hormone which is synthesized in the liver and dominantly regulates the process of megakaryocytopoiesis (9). TPO acts on c-MpL receptor on the surface of megakaryocytes and stimulates various steps of platelet production within the bone marrow (10). TPO generation in turn is regulated by the rate of platelet cycling (production and destruction), as well as the synthetic function of liver (11). Several studies have argued about the relative majority influence on this multifactorial etiology of thrombocytopenia in CLD (11). Romiplostim and eltrombopag were developed as successful first generation TPO receptor agonists. Romiplostim is indicated for thrombocytopenia d","PeriodicalId":72814,"journal":{"name":"Digestive medicine research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49451251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent advancements in laboratory screening, diagnosis, and prognosis of biliary atresia: a literature review 胆道闭锁实验室筛查、诊断及预后的最新进展:文献综述
Pub Date : 2021-09-01 DOI: 10.21037/dmr-21-52
B. Sun, Sarah Kelleher, Celia Short, Patricio Arias Valencia, J. Zagory
Biliary atresia (BA) is a neonatal cholangiopathy associated with fibrotic obliteration of the extrahepatic biliary tree leading to profound cholestasis and progressive liver failure (1,2). The incidence of BA is variable, estimated to range from 1 in 3,000 to 1 in 18,000 live births, and is more common in Taiwan, China, and Japan (3-6). Although relatively rare, BA is the most common cause of liver failure in children and is the leading indication for pediatric liver transplant (5,7-11). Unfortunately, without treatment, BA is universally lethal by 2 years of age (6,12). Aside from liver transplantation, the only treatment for BA is the Kasai portoenterostomy (KPE), a surgical procedure Review Article
胆道闭锁(BA)是一种新生儿胆管疾病,与肝外胆道树纤维化闭塞相关,可导致重度胆汁淤积和进行性肝功能衰竭(1,2)。BA的发病率是可变的,估计范围从1 / 3000到1 / 18000活产婴儿,在台湾、中国大陆和日本更为常见(3-6)。虽然相对罕见,但BA是儿童肝功能衰竭的最常见原因,也是儿童肝移植的主要适应症(5,7-11)。不幸的是,如果不进行治疗,BA在2岁时普遍是致命的(6,12)。除了肝移植,治疗BA的唯一方法是Kasai门肠造口术(KPE),这是一种外科手术
{"title":"Recent advancements in laboratory screening, diagnosis, and prognosis of biliary atresia: a literature review","authors":"B. Sun, Sarah Kelleher, Celia Short, Patricio Arias Valencia, J. Zagory","doi":"10.21037/dmr-21-52","DOIUrl":"https://doi.org/10.21037/dmr-21-52","url":null,"abstract":"Biliary atresia (BA) is a neonatal cholangiopathy associated with fibrotic obliteration of the extrahepatic biliary tree leading to profound cholestasis and progressive liver failure (1,2). The incidence of BA is variable, estimated to range from 1 in 3,000 to 1 in 18,000 live births, and is more common in Taiwan, China, and Japan (3-6). Although relatively rare, BA is the most common cause of liver failure in children and is the leading indication for pediatric liver transplant (5,7-11). Unfortunately, without treatment, BA is universally lethal by 2 years of age (6,12). Aside from liver transplantation, the only treatment for BA is the Kasai portoenterostomy (KPE), a surgical procedure Review Article","PeriodicalId":72814,"journal":{"name":"Digestive medicine research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45375603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neoadjuvant double metal stent placement in a patient with locally unresectable cancer of the panceatic head—a case report 一例局部不能切除的癌症患者的新辅助双金属支架置入术
Pub Date : 2021-09-01 DOI: 10.21037/dmr-21-31
H. Wittenburg, Thomas Kirchner, L. Partecke
: Pancreatic cancer still has a poor prognosis and the only curative treatment that also leads to longest survival is surgical resection. However, due to poor performance status, locally advanced disease, or metastases only a minority of patients are candidates for surgery. On the other hand, newer and more potent neoadjuvant chemotherapy regimes may render locally advanced tumors resectable and when resection is achieved, resection results in improved prognosis. Cancer of the pancreatic head frequently cause biliary and duodenal obstruction that needs to be resolved prior to application of chemotherapy. Here we report the case of a 72-year-old patient who we diagnosed with cancer of the pancreatic head. At the time of diagnosis, cross-sectional imaging displayed no metastases. Histology of the tumor was confirmed by open surgery but the tumor was locally unresectable at the time of first exploration. Subsequently, the patient developed both jaundice and duodenal obstruction, therefore we performed “neoadjuvant” double metal stenting of the duodenum and the bile duct. The procedure involved an external-internal rendez-vous procedure that resulted in complete relief from biliary and gastric obstruction and enabled the patient to receive timely pre-operative chemotherapy.
:癌症的预后仍然很差,唯一能延长生存期的治疗方法是手术切除。然而,由于表现不佳、局部晚期疾病或转移,只有少数患者可以接受手术。另一方面,更新和更有效的新辅助化疗方案可能使局部晚期肿瘤可切除,当实现切除时,切除可改善预后。胰头癌症经常引起胆道和十二指肠梗阻,需要在应用化疗前解决。在这里,我们报告了一例72岁的患者,我们诊断为胰头癌症。在诊断时,横断面成像显示没有转移。肿瘤的组织学通过开放手术得到证实,但在第一次探查时肿瘤局部无法切除。随后,患者出现黄疸和十二指肠梗阻,因此我们对十二指肠和胆管进行了“新辅助”双金属支架植入术。该手术包括一种内外部rendez-vous手术,完全缓解了胆道和胃梗阻,使患者能够及时接受术前化疗。
{"title":"Neoadjuvant double metal stent placement in a patient with locally unresectable cancer of the panceatic head—a case report","authors":"H. Wittenburg, Thomas Kirchner, L. Partecke","doi":"10.21037/dmr-21-31","DOIUrl":"https://doi.org/10.21037/dmr-21-31","url":null,"abstract":": Pancreatic cancer still has a poor prognosis and the only curative treatment that also leads to longest survival is surgical resection. However, due to poor performance status, locally advanced disease, or metastases only a minority of patients are candidates for surgery. On the other hand, newer and more potent neoadjuvant chemotherapy regimes may render locally advanced tumors resectable and when resection is achieved, resection results in improved prognosis. Cancer of the pancreatic head frequently cause biliary and duodenal obstruction that needs to be resolved prior to application of chemotherapy. Here we report the case of a 72-year-old patient who we diagnosed with cancer of the pancreatic head. At the time of diagnosis, cross-sectional imaging displayed no metastases. Histology of the tumor was confirmed by open surgery but the tumor was locally unresectable at the time of first exploration. Subsequently, the patient developed both jaundice and duodenal obstruction, therefore we performed “neoadjuvant” double metal stenting of the duodenum and the bile duct. The procedure involved an external-internal rendez-vous procedure that resulted in complete relief from biliary and gastric obstruction and enabled the patient to receive timely pre-operative chemotherapy.","PeriodicalId":72814,"journal":{"name":"Digestive medicine research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48718844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Endoscopic biliary drainage for distal biliary stenosis: a narrative review of current status and future prospects 胆道远端狭窄的内镜下胆道引流:现状和未来前景的叙述性回顾
Pub Date : 2021-09-01 DOI: 10.21037/dmr-21-55
Naosuke Kuraoka, S. Hashimoto, S. Matsui, S. Terai
{"title":"Endoscopic biliary drainage for distal biliary stenosis: a narrative review of current status and future prospects","authors":"Naosuke Kuraoka, S. Hashimoto, S. Matsui, S. Terai","doi":"10.21037/dmr-21-55","DOIUrl":"https://doi.org/10.21037/dmr-21-55","url":null,"abstract":"","PeriodicalId":72814,"journal":{"name":"Digestive medicine research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45237804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Donor quality of life after living donor liver transplantation: a review of the literature 活体肝移植后供者的生活质量:文献综述
Pub Date : 2021-09-01 DOI: 10.21037/dmr-20-151
A. Thuluvath, J. Peipert, R. Berkowitz, O. Siddiqui, Bridget Whitehead, Arielle Thomas, J. Levitsky, J. Caicedo-Ramirez, D. Ladner
Living donor liver transplantation (LDLT) provides a source for transplant in the setting of the deceased donor organ shortage. Seeing as living donors do not derive any medical benefit from the procedure, fully understanding the impact of donation on donor health-related quality of life (HRQOL) is essential. A systematic search of the MEDLINE database was performed from 2008–2020, using relevant Medical Subject Headings. Articles were evaluated for study design, cohort size and follow-up time and excluded if they contained significant methodological flaws. A total of 43 articles were included: 20 (47%) were cross-sectional and 23 (53%) were longitudinal. The mean number of donors per study was 142 (range:8–578) with follow-up ranging from 12–132 months. Forty-two unique HRQOL metrics were implemented across the 43 studies, the majority of which were questionnaires. Of the 31 studies that used the Medical Outcomes Study Short Form 36 questionnaire, 9.1% of donors reported physical QOL did not return to pre-LDLT levels for at least 2 years after donation. Mental QOL remained stable or improved after LDLT, with mean mental composite scores increasing from 50 to 52 at 3 months post-LDLT in one study. The predicted probability of poor sexual desire decreased at 1-year post-LDLT (male: 0.08, female: 0.26) relative to pre-LDLT (male: 0.44, female: 0.76; P<0.001) and three months post-LDLT (male: 0.35, female 0.69; P=0.001). Forty percent of donors found LDLT to be financially burdensome at 3 months and 19% at 2 years post-LDLT. Female gender and obesity were consistent predictors of worse HRQOL. Laparoscopy-assisted donor hepatectomy was associated with shorter hospitalizations than open donor hepatectomy (10.3 vs. 18.3 days, P=0.02). No studies used the National Institutes of Health Patient Reported Outcomes Measurement Information System (PROMIS) measures of HRQOL. Our review demonstrates that LDLT can have a long-lasting negative impact on physical QOL in 9.1% of donors and can cause both sexual dysfunction and significant financial strain. Future studies should consider using standardized and extensively validated patient reported outcomes measures, such as PROMIS, in order to directly compare outcomes across studies and gain further insight into the impact of LDLT on D-HRQOL.
活体肝移植(LDLT)为已故供体器官短缺的情况下的移植提供了来源。鉴于活体捐赠者不会从手术中获得任何医疗利益,充分了解捐赠对捐赠者健康相关生活质量(HRQOL)的影响至关重要。2008年至2020年,使用相关医学主题标题对MEDLINE数据库进行了系统搜索。根据研究设计、队列规模和随访时间对文章进行评估,如果文章包含重大方法学缺陷,则将其排除在外。共纳入43篇文章:20篇(47%)为横断面文章,23篇(53%)为纵向文章。每项研究的平均捐献者人数为142人(范围:8-578人),随访时间为12-132个月。在43项研究中实施了42项独特的HRQOL指标,其中大多数是问卷调查。在使用医学结果研究简表36问卷的31项研究中,9.1%的捐赠者报告称,在捐赠后至少2年内,身体生活质量没有恢复到LDLT前的水平。在一项研究中,LDLT后精神生活质量保持稳定或改善,LDLT 3个月时平均精神综合评分从50分增加到52分。与LDLT前(男性:0.44,女性:0.76;P<0.001)和LDLT后三个月(男性:0.35,女性:0.69;P=0.001)相比,LDLT后1年(男性:0.08,女性:0.26),性欲低下的预测概率降低。40%的捐赠者发现LDLT在LDLT后3个月和2年分别有19%和19%的人感到经济负担。女性和肥胖是HRQOL恶化的一致预测因素。腹腔镜辅助供肝切除术与开放供肝切除手术相比住院时间更短(10.3天vs.18.3天,P=0.02)。没有研究使用美国国立卫生研究院患者报告结果测量信息系统(PROMIS)的HRQOL测量。我们的综述表明,LDLT会对9.1%的捐赠者的身体生活质量产生长期的负面影响,并可能导致性功能障碍和严重的经济压力。未来的研究应考虑使用标准化和广泛验证的患者报告结果测量,如PROMIS,以便直接比较研究结果,并进一步了解LDLT对D-HRQOL的影响。
{"title":"Donor quality of life after living donor liver transplantation: a review of the literature","authors":"A. Thuluvath, J. Peipert, R. Berkowitz, O. Siddiqui, Bridget Whitehead, Arielle Thomas, J. Levitsky, J. Caicedo-Ramirez, D. Ladner","doi":"10.21037/dmr-20-151","DOIUrl":"https://doi.org/10.21037/dmr-20-151","url":null,"abstract":"Living donor liver transplantation (LDLT) provides a source for transplant in the setting of the deceased donor organ shortage. Seeing as living donors do not derive any medical benefit from the procedure, fully understanding the impact of donation on donor health-related quality of life (HRQOL) is essential. A systematic search of the MEDLINE database was performed from 2008–2020, using relevant Medical Subject Headings. Articles were evaluated for study design, cohort size and follow-up time and excluded if they contained significant methodological flaws. A total of 43 articles were included: 20 (47%) were cross-sectional and 23 (53%) were longitudinal. The mean number of donors per study was 142 (range:8–578) with follow-up ranging from 12–132 months. Forty-two unique HRQOL metrics were implemented across the 43 studies, the majority of which were questionnaires. Of the 31 studies that used the Medical Outcomes Study Short Form 36 questionnaire, 9.1% of donors reported physical QOL did not return to pre-LDLT levels for at least 2 years after donation. Mental QOL remained stable or improved after LDLT, with mean mental composite scores increasing from 50 to 52 at 3 months post-LDLT in one study. The predicted probability of poor sexual desire decreased at 1-year post-LDLT (male: 0.08, female: 0.26) relative to pre-LDLT (male: 0.44, female: 0.76; P<0.001) and three months post-LDLT (male: 0.35, female 0.69; P=0.001). Forty percent of donors found LDLT to be financially burdensome at 3 months and 19% at 2 years post-LDLT. Female gender and obesity were consistent predictors of worse HRQOL. Laparoscopy-assisted donor hepatectomy was associated with shorter hospitalizations than open donor hepatectomy (10.3 vs. 18.3 days, P=0.02). No studies used the National Institutes of Health Patient Reported Outcomes Measurement Information System (PROMIS) measures of HRQOL. Our review demonstrates that LDLT can have a long-lasting negative impact on physical QOL in 9.1% of donors and can cause both sexual dysfunction and significant financial strain. Future studies should consider using standardized and extensively validated patient reported outcomes measures, such as PROMIS, in order to directly compare outcomes across studies and gain further insight into the impact of LDLT on D-HRQOL.","PeriodicalId":72814,"journal":{"name":"Digestive medicine research","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41515551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Robotic primary bariatric surgery 机器人初级减肥手术
Pub Date : 2021-09-01 DOI: 10.21037/dmr-21-33
V. Bindal, D. Sethi, Dhananjay Pandey
In the last two decades, significant growth in the field of robotic bariatric surgery has been noted. Major advantage provided by robotic platform is its three-dimensional, high definition vision, improved degrees of freedom and better precision by taking care of physiological tremors. In improves surgical ergonomics by nullifying excessive torque placed on ports due to thick abdominal wall and thus reduces port site trauma. However, robotic bariatric surgery is perceived to be associated with increased operative time as well as cost. The benefits provided to the patient are also debatable when compared to laparoscopy. Also, there is a learning curve to robotic surgery, which requires team training. In this manuscript, we will discuss the detailed techniques of the commonly performed robotic bariatric procedures. In laparoscopic bariatric surgery anastomosis is usually stapled while it is usually performed in hand sewn fashion when using robotic platform. That leads to difference in operative metrics and postoperative results. We will also discuss the published evidence to support or refute the role of robotic surgery in each of these primary bariatric procedures. With advancements and new platforms being introduced in the field of robotic surgery, there is likely to be a rapid increase in access to this technology.
在过去的二十年里,机器人减肥手术领域的显著增长已经被注意到。机器人平台的主要优势是其三维,高清晰度的视觉,提高的自由度和更好的精度,通过照顾生理震动。它通过消除由于腹壁厚而施加在端口上的过大扭矩,从而减少端口部位的创伤,从而改善了手术的人体工程学。然而,人们认为机器人减肥手术会增加手术时间和成本。与腹腔镜相比,提供给患者的好处也是有争议的。此外,机器人手术有一个学习曲线,需要团队训练。在这篇文章中,我们将讨论常用的机器人减肥手术的详细技术。在腹腔镜减肥手术中,吻合术通常采用吻合术,而使用机器人平台时,吻合术通常采用手缝方式。这导致了手术指标和术后结果的差异。我们还将讨论已发表的证据,以支持或反驳机器人手术在这些主要减肥手术中的作用。随着机器人手术领域的进步和新平台的引入,这项技术的使用可能会迅速增加。
{"title":"Robotic primary bariatric surgery","authors":"V. Bindal, D. Sethi, Dhananjay Pandey","doi":"10.21037/dmr-21-33","DOIUrl":"https://doi.org/10.21037/dmr-21-33","url":null,"abstract":"In the last two decades, significant growth in the field of robotic bariatric surgery has been noted. Major advantage provided by robotic platform is its three-dimensional, high definition vision, improved degrees of freedom and better precision by taking care of physiological tremors. In improves surgical ergonomics by nullifying excessive torque placed on ports due to thick abdominal wall and thus reduces port site trauma. However, robotic bariatric surgery is perceived to be associated with increased operative time as well as cost. The benefits provided to the patient are also debatable when compared to laparoscopy. Also, there is a learning curve to robotic surgery, which requires team training. In this manuscript, we will discuss the detailed techniques of the commonly performed robotic bariatric procedures. In laparoscopic bariatric surgery anastomosis is usually stapled while it is usually performed in hand sewn fashion when using robotic platform. That leads to difference in operative metrics and postoperative results. We will also discuss the published evidence to support or refute the role of robotic surgery in each of these primary bariatric procedures. With advancements and new platforms being introduced in the field of robotic surgery, there is likely to be a rapid increase in access to this technology.","PeriodicalId":72814,"journal":{"name":"Digestive medicine research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48442455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Laparoscopic vs. robotic surgery: What is the data? 腹腔镜手术与机器人手术:数据是什么?
Pub Date : 2021-09-01 DOI: 10.21037/dmr-21-65
E. Dogeas, D. Geller
© Digestive Medicine Research. All rights reserved. Dig Med Res 2021;4:42 | https://dx.doi.org/10.21037/dmr-21-65 Laparoscopic liver surgery (LLS) is rapidly expanding including laparoscopic major hepatectomy (1), and studies have demonstrated that LLS has several important peri-operative clinical benefits over open hepatectomy including less blood loss, less narcotic requirement, fewer complications, and reduced hospital stay (2,3). Furthermore, three randomized clinical trials have shown that LLS performed for primary or secondary hepatic malignancies does not compromise oncologic outcomes compared again to open hepatectomy (4-6). Robotic liver surgery (RLS) was first reported in 2003 and has since been regarded as the next step in the evolution of minimally-invasive hepatectomy (7). The robotic surgery platforms have several inherent technical features that are appealing to the hepatic surgeon. These features include articulating instruments with more degrees of freedom than conventional laparoscopic instruments, tremor filtering, a surgical endoscope with 3D and magnified view that is controlled by the surgeon and improved comfort and ergonomics for the console surgeon. These combined features lead to less reliance on the assistant surgeon and allow the operating surgeon to perform complex maneuvers such as intracorporeal suturing and vessel dissection with more ease. Theoretical disadvantages of RLS include the lack of haptic feedback, longer operating time due to the required additional steps to “dock” and “undock” the robotic platform and higher costs compared to LLS. Indeed, Tsung et al. in a matched comparison of 57 robotic liver resections with 114 laparoscopic cases, reported similar peri-operative outcomes, but a significantly longer median operative time for RLS (253 vs. 199 minutes) (8). The 2018 International consensus statement on robotic hepatectomy surgery summarizes the recent literature on RLS and concludes that it is a safe and feasible as traditional open hepatectomy, but it is associated with longer operating times, less intraoperative blood loss, shorter length of stay and fewer complications when compared to open liver surgery (7). In terms of minimally-invasive major hepatectomy, both laparoscopic and robotic approaches appear to have equivalent peri-/postoperative outcomes when performed in select patients and high-volume centers according to a recent meta-analysis by Ziogas et al., which included seven studies with a total of 300 laparoscopic and 225 robotic major hepatectomies (9). However, other smaller studies have suggested that RLS is associated with higher intraoperative blood loss and longer operative time compared to LLS (10,11). In terms of long-term oncologic outcomes, a recent propensity-matched analysis of patients who underwent LLS (n=514) or RLS (n=115) for colorectal cancer liver metastasis reported equivalent 5-year overallsurvival (OS) and disease-free survival (DFS) between the two groups (12). Regard
©消化医学研究。保留所有权利。Dig Med Res 2021;4:42 |https://dx.doi.org/10.21037/dmr-21-65腹腔镜肝脏手术(LLS)正在迅速扩大,包括腹腔镜大肝切除术(1),研究表明,LLS比开放式肝切除术具有几个重要的围手术期临床益处,包括减少失血、减少麻醉需求、减少并发症和缩短住院时间(2,3)。此外,三项随机临床试验表明,与开放性肝切除术相比,对原发性或继发性肝脏恶性肿瘤进行LLS不会影响肿瘤学结果(4-6)。机器人肝脏手术(RLS)于2003年首次报道,此后被视为微创肝切除术发展的下一步(7)。机器人手术平台具有吸引肝脏外科医生的几个固有技术特征。这些功能包括比传统腹腔镜器械具有更多自由度的关节式器械、震颤过滤、由外科医生控制的具有3D和放大视图的外科内窥镜,以及控制台外科医生的舒适性和人体工程学改进。这些综合特征减少了对助理外科医生的依赖,并使手术外科医生能够更容易地进行复杂的操作,如体内缝合和血管解剖。RLS的理论缺点包括缺乏触觉反馈,由于需要额外的步骤来“对接”和“脱离”机器人平台,操作时间更长,以及与LLS相比成本更高。事实上,Tsung等人在对57例机器人肝脏切除术和114例腹腔镜病例的匹配比较中,报告了类似的围手术期结果,但RLS的中位手术时间明显更长(253分钟对199分钟)(8)。2018年关于机器人肝切除术的国际共识声明总结了RLS的最新文献,并得出结论,它与传统的开放式肝切除术一样安全可行,但与开放式肝手术相比,它与更长的手术时间、更少的术中失血、更短的停留时间和更少的并发症有关(7)。根据Ziogas等人最近的一项荟萃分析,就微创大肝切除术而言,在选定的患者和大容量中心进行腹腔镜和机器人方法似乎具有同等的围术期/术后结果,该荟萃分析包括7项研究,共有300例腹腔镜和225例机器人大肝切除(9)。然而,其他较小的研究表明,与LLS相比,RLS与更高的术中失血量和更长的手术时间有关(10,11)。就长期肿瘤结果而言,最近对接受LLS(n=514)或RLS(n=115)治疗结直肠癌癌症肝转移的患者进行的倾向匹配分析报告,两组患者的5年总生存率(OS)和无病生存率(DFS)相等(12)。关于成本,LLS已被证明与开放式肝切除术相比具有成本效益,平均总成本降低17%(13)。当比较LLS和RLS之间的成本时,几项研究表明,与机器人平台的使用相关的成本更高(14)。在一项对38项研究的大型荟萃分析中,包括1674名接受LLS的患者和390名RLS患者,Ziogas等人显示手术室成本更高
{"title":"Laparoscopic vs. robotic surgery: What is the data?","authors":"E. Dogeas, D. Geller","doi":"10.21037/dmr-21-65","DOIUrl":"https://doi.org/10.21037/dmr-21-65","url":null,"abstract":"© Digestive Medicine Research. All rights reserved. Dig Med Res 2021;4:42 | https://dx.doi.org/10.21037/dmr-21-65 Laparoscopic liver surgery (LLS) is rapidly expanding including laparoscopic major hepatectomy (1), and studies have demonstrated that LLS has several important peri-operative clinical benefits over open hepatectomy including less blood loss, less narcotic requirement, fewer complications, and reduced hospital stay (2,3). Furthermore, three randomized clinical trials have shown that LLS performed for primary or secondary hepatic malignancies does not compromise oncologic outcomes compared again to open hepatectomy (4-6). Robotic liver surgery (RLS) was first reported in 2003 and has since been regarded as the next step in the evolution of minimally-invasive hepatectomy (7). The robotic surgery platforms have several inherent technical features that are appealing to the hepatic surgeon. These features include articulating instruments with more degrees of freedom than conventional laparoscopic instruments, tremor filtering, a surgical endoscope with 3D and magnified view that is controlled by the surgeon and improved comfort and ergonomics for the console surgeon. These combined features lead to less reliance on the assistant surgeon and allow the operating surgeon to perform complex maneuvers such as intracorporeal suturing and vessel dissection with more ease. Theoretical disadvantages of RLS include the lack of haptic feedback, longer operating time due to the required additional steps to “dock” and “undock” the robotic platform and higher costs compared to LLS. Indeed, Tsung et al. in a matched comparison of 57 robotic liver resections with 114 laparoscopic cases, reported similar peri-operative outcomes, but a significantly longer median operative time for RLS (253 vs. 199 minutes) (8). The 2018 International consensus statement on robotic hepatectomy surgery summarizes the recent literature on RLS and concludes that it is a safe and feasible as traditional open hepatectomy, but it is associated with longer operating times, less intraoperative blood loss, shorter length of stay and fewer complications when compared to open liver surgery (7). In terms of minimally-invasive major hepatectomy, both laparoscopic and robotic approaches appear to have equivalent peri-/postoperative outcomes when performed in select patients and high-volume centers according to a recent meta-analysis by Ziogas et al., which included seven studies with a total of 300 laparoscopic and 225 robotic major hepatectomies (9). However, other smaller studies have suggested that RLS is associated with higher intraoperative blood loss and longer operative time compared to LLS (10,11). In terms of long-term oncologic outcomes, a recent propensity-matched analysis of patients who underwent LLS (n=514) or RLS (n=115) for colorectal cancer liver metastasis reported equivalent 5-year overallsurvival (OS) and disease-free survival (DFS) between the two groups (12). Regard","PeriodicalId":72814,"journal":{"name":"Digestive medicine research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42326457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Digestive medicine research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1